评估CRBN突变对多发性骨髓瘤患者免疫调节药物及新型cereblon E3连接酶调节剂反应的影响
本研究通过建模选定的CRBN错义突变,分析其对CRBN功能的影响,并探讨新型cereblon E3连接酶调节剂(CELMoDs)能否克服对IMiD作用有害的突变。结果显示三种反应模式:完全丧失CRBN功能、无影响及药物依赖性效应;后者中4个突变经证实可被更强效CELMoDs克服,基于新晶体结构的动态建模有助于理解这些突变的影响。
要点
- CRBN错义突变对IMiD反应呈现完全丧失、无影响和药物依赖性三种模式。
- 部分CRBN突变虽导致IMiD耐药,但更强效CELMoDs仍可诱导新底物降解和细胞死亡。
- CRBN测序结果解读需区分突变类型,以指导后续治疗选择。
核心结论
- CRBN错义突变对IMiD反应存在异质性,部分突变可被CELMoDs克服,对解读CRBN测序结果和后续治疗决策有重要意义。
研究设计与样本
- 本研究对选定的CRBN错义突变进行建模,并检测其对CRBN功能的影响,同时分析CELMoDs能否克服对IMiD作用有害的突变。
主要发现
- CRBN错义突变呈现三种反应模式:导致所有药物完全丧失CRBN功能、对CRBN功能无影响、以及药物依赖性效应。
- 对4个药物依赖性效应突变进行更详细分析,证实更强效CELMoDs在IMiDs无活性时仍能导致新底物降解和细胞死亡。
- 基于新生成的DDB1/CRBN/来那度胺复合物晶体结构(分辨率高于已发表结构)的动态建模有助于理解这些突变的影响。
临床怎么用
- 作者认为,这些结果对解读患者CRBN测序结果以指导未来治疗决策有重要意义,尤其有助于识别那些尽管使用IMiDs后复发且携带CRBN突变、但仍可能从CELMoD药物中获益的患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunomodulatory drug (IMiD) resistance is a key clinical challenge in myeloma treatment. Previous data suggest almost one-third of myeloma patients acquire genetic alteration of the key IMiD effector cereblon (CRBN) by the time they are pomalidomide refractory. Some events, including stop codons/frameshift mutations and copy loss, have clearly explicable effects on CRBN protein function. Missense mutations have also been reported throughout the length of CRBN but their functional impact has not been systematically studied. This study modeled selected missense mutations and examined their effect on CRBN function also analyzing whether any mutations deleterious to IMiD action could be overcome using the novel cereblon E3 ligase modulators (CELMoDs). Three patterns of response to missense mutations were apparent: mutations that led to complete loss of CRBN function for all agents, those that had no effect on CRBN function, and those with agent-dependent effect on CRBN function. The latter group of 4 mutations were profiled in more detail with confirmatory experiments demonstrating an ability of the more potent CELMoDs to lead to neosubstrate degradation and cell death even though IMiDs were not active. Dynamic modeling based on a newly generated crystal structure of the DDB1/CRBN/lenalidomide complex, with greater resolution than those published to date, helped to understand the impact of these mutations. These results have important implications for the interpretation of CRBN sequencing results from patients for future therapy decisions, particularly differentiating those who may, despite relapsing on IMiDs with CRBN mutations, have the potential to still benefit from the use of CELMoD agents.
引用
- Chrisochoidou Y, Scarpino A, Morales S, et al. Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma. Blood. 2025. PMID: 39841463. doi:10.1182/blood.2024025861
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。